ProductUpdated on 1 September 2025
ORCA-010: Enhanced Oncolytic Immunotherapy Platform with 100% Immune Activation Success
About
ORCA-010 is a breakthrough enhanced oncolytic immunotherapy platform achieving unprecedented 100% immune activation in cancer patients. Our technology consistently converts "cold" tumors to "hot" with >70x enhanced potency compared to existing oncolytic platforms.
Proven clinical results in prostate cancer include durable PSA decrease in 50% of patients and cancer-free biopsies in 33% at one-year follow-up, with excellent safety profile (Grade I-II AEs only, no MTD reached).
Our diversified pipeline targets high-value opportunities:
-
Metastatic prostate cancer (pivotal trial planned)
-
Recurrent glioblastoma (academic collaboration initiated)
-
Pediatric DIPG (orphan designation potential)
-
Pancreatic adenocarcinoma (high unmet need)
ORCA-010's platform approach enables expansion across multiple orphan oncology indications where immune activation could transform patient outcomes. The technology's ability to induce systemic anti-tumor responses creates opportunities for both monotherapy and combination strategies.
We seek strategic partnerships for co-development, licensing, or acquisition discussions across our indication portfolio, particularly in prostate cancer and rare oncology diseases with significant unmet medical need.
Best regards,
Wen
Wenliang Dong, PhD, MBA
Contact: wen.dong@orca-therapeutics.com
Similar opportunities
Project cooperation
Neo-adjuvant oncolytic immune activator
Wenliang Dong
CEO at ORCA Therapeutics BV
Amsterdam, Netherlands
Service
Viral Vector Development & Manufacturing
- Development
- Manufacturing
- Innovative therapies - Gene therapy
- Innovative therapies - Oncolytic viruses
Sophia Kolbe
Business Developer at NecstGen
Leiden, Netherlands
Service
Oncolines cancer cell panel profiling
- Consulting
- Development
- Innovative therapies - Precision medicine
- Innovative therapies - Immune cell therapy
- Innovative human-based test models - 3D spheroids
- Innovative human-based test models - 2D & 3D in vitro cell culture models
- Development stages and support fuctions - Clinical research and development
- Development stages and support fuctions - Pre-clinical research and development
Guido Zaman
Managing Director at Oncolines B.V.
Oss, Netherlands